Jabbour et al evaluated factors affecting the response of patient with Ph+ chronic myeloid leukemia (CML) in chronic phase to nilotinib. The authors are from multiple hospitals in the Europe and North America.


Patient selection: Ph+ CML, resistant to or intolerant of imatinib, treated with nilotinib


Outcomes: progression-free survival, overall survival


Factors associated with worse outcomes (3 known at baseline, 1 known within 12 months):

(1) baseline hemoglobin < 12 g/dL

(2) baseline percent basophils >= 4%

(3) baseline mutation with low sensitivity to nilotinib

(4) absence of major cytogenetic respsonse within 12 months (drug resistance)


Outcomes were best when all 4 factors were absent and worst when all 4 were present.


To read more or access our algorithms and calculators, please log in or register.